We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
Read MoreHide Full Article
Key Takeaways
Spyre is testing SPY072 plus bimekizumab versus bimekizumab alone in about 150 HS patients.
The SKYLIGHT trial's week-16 HiSCR75 endpoint is expected to provide topline data in late 2027 or early 2028.
Spyre's HS move broadens its pipeline beyond IBD and rheumatology but adds clinical and funding demands.
Spyre Therapeutics (SYRE - Free Report) expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS. The move takes its combination approach into a new disease area beyond inflammatory bowel disease and rheumatology.
The opportunity is broader pipeline optionality, but the clinical bar is clear. SKYLIGHT must show that adding TL1A inhibition to an IL-17A/F backbone can improve outcomes enough to justify further development.
Spyre Brings Dual-Pathway Inhibition to HS
SPY772 combines SPY072, a long-acting anti-TL1A antibody, with SPY007, a long-acting anti-IL-17A/F antibody. The program extends Spyre's strategy of attacking more than one inflammatory pathway at the same time.
That approach is already central to its IBD pipeline, where pairwise combinations target alpha 4 beta 7, TL1A and IL-23. Moving the concept into HS gives Spyre a chance to test whether its combination thesis can travel beyond gastrointestinal disease.
SYRE's SKYLIGHT Trial Has a Clear 16-Week Test
SKYLIGHT is evaluating SPY072 plus bimekizumab against bimekizumab alone in approximately 150 adults with moderate-to-severe HS. The primary endpoint is the HiSCR75 response rate at week 16, with topline data expected in late 2027 or early 2028.
The design tests whether adding SPY072 to bimekizumab can improve the week-16 response rate relative to bimekizumab alone. Positive results could support further SPY772 development in HS and other indications.
Spyre Extends Its Platform Beyond IBD and Rheumatology
HS adds another disease area to a pipeline that already spans ulcerative colitis, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Spyre is also advancing multiple IBD monotherapies and dual-antibody combinations, giving the company several mechanisms and readouts to evaluate.
Competition in HS is active. AbbVie (ABBV - Free Report) has an established presence through Humira and is developing ABBV-1451, an IL-1 alpha/beta antibody for HS. Incyte (INCY - Free Report) has an FDA-accepted New Drug Application for povorcitinib in moderate-to-severe HS, with a U.S. launch targeted for the first quarter of 2027 if approved.
SYRE Adds Optionality but Also Execution Demands
A broader pipeline reduces dependence on any one study, but it also raises the amount of clinical and manufacturing work Spyre must fund. Research and development expenses rose 63.2% year over year to $65.5 million in the second quarter of 2026 as manufacturing, clinical study and headcount costs increased.
Spyre ended the quarter with $1.15 billion in cash, cash equivalents and marketable securities. Management expects that position to fund operations into the second half of 2029, although the company is still expected to need significant additional funding as development advances.
SYRE's Scores Favor Watching the New Catalyst
SKYLIGHT gives Spyre another important proof point for whether its multi-pathway strategy can support growth beyond core IBD. The study is still early, and the larger investment case remains exposed to clinical development risk, rising cash burn and intense competition.
SYRE currently carries a Zacks Rank #3 (Hold), so it is not among the #1 (Strong Buy) or #2 (Buy) stocks that the Zacks framework identifies as the most favorable short-term candidates. Its Momentum Score of A points to favorable price-trend characteristics, while its Value Score of F, Growth Score of F and VGM Score of F show weaker standing on those styles. That mix supports monitoring the clinical catalyst without treating the current momentum signal as a complete investment case. You can see the complete list of today’s Zacks #1 Rank stocks here.
View the Zacks #1 Rank List
Image: Bigstock
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
Key Takeaways
Spyre Therapeutics (SYRE - Free Report) expanded its inflammatory-disease strategy in August with SPY772 and the phase II SKYLIGHT study in hidradenitis suppurativa, or HS. The move takes its combination approach into a new disease area beyond inflammatory bowel disease and rheumatology.
The opportunity is broader pipeline optionality, but the clinical bar is clear. SKYLIGHT must show that adding TL1A inhibition to an IL-17A/F backbone can improve outcomes enough to justify further development.
Spyre Brings Dual-Pathway Inhibition to HS
SPY772 combines SPY072, a long-acting anti-TL1A antibody, with SPY007, a long-acting anti-IL-17A/F antibody. The program extends Spyre's strategy of attacking more than one inflammatory pathway at the same time.
That approach is already central to its IBD pipeline, where pairwise combinations target alpha 4 beta 7, TL1A and IL-23. Moving the concept into HS gives Spyre a chance to test whether its combination thesis can travel beyond gastrointestinal disease.
SYRE's SKYLIGHT Trial Has a Clear 16-Week Test
SKYLIGHT is evaluating SPY072 plus bimekizumab against bimekizumab alone in approximately 150 adults with moderate-to-severe HS. The primary endpoint is the HiSCR75 response rate at week 16, with topline data expected in late 2027 or early 2028.
The design tests whether adding SPY072 to bimekizumab can improve the week-16 response rate relative to bimekizumab alone. Positive results could support further SPY772 development in HS and other indications.
Spyre Therapeutics, Inc. Price and Consensus
Spyre Therapeutics, Inc. price-consensus-chart | Spyre Therapeutics, Inc. Quote
Spyre Extends Its Platform Beyond IBD and Rheumatology
HS adds another disease area to a pipeline that already spans ulcerative colitis, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Spyre is also advancing multiple IBD monotherapies and dual-antibody combinations, giving the company several mechanisms and readouts to evaluate.
Competition in HS is active. AbbVie (ABBV - Free Report) has an established presence through Humira and is developing ABBV-1451, an IL-1 alpha/beta antibody for HS. Incyte (INCY - Free Report) has an FDA-accepted New Drug Application for povorcitinib in moderate-to-severe HS, with a U.S. launch targeted for the first quarter of 2027 if approved.
SYRE Adds Optionality but Also Execution Demands
A broader pipeline reduces dependence on any one study, but it also raises the amount of clinical and manufacturing work Spyre must fund. Research and development expenses rose 63.2% year over year to $65.5 million in the second quarter of 2026 as manufacturing, clinical study and headcount costs increased.
Spyre ended the quarter with $1.15 billion in cash, cash equivalents and marketable securities. Management expects that position to fund operations into the second half of 2029, although the company is still expected to need significant additional funding as development advances.
SYRE's Scores Favor Watching the New Catalyst
SKYLIGHT gives Spyre another important proof point for whether its multi-pathway strategy can support growth beyond core IBD. The study is still early, and the larger investment case remains exposed to clinical development risk, rising cash burn and intense competition.
SYRE currently carries a Zacks Rank #3 (Hold), so it is not among the #1 (Strong Buy) or #2 (Buy) stocks that the Zacks framework identifies as the most favorable short-term candidates. Its Momentum Score of A points to favorable price-trend characteristics, while its Value Score of F, Growth Score of F and VGM Score of F show weaker standing on those styles. That mix supports monitoring the clinical catalyst without treating the current momentum signal as a complete investment case. You can see the complete list of today’s Zacks #1 Rank stocks here.